Mr. Lu was the Founder of Biosensors International Group and served as its Chairman and CEO from inception to 2008. He retained his leadership position as Chairman of Biosensors from January 2008 until November 2016 after it was acquired by Citic for SGD$1.1B.
Mr. Lu has more than 30 years’ experience in the medical industry. Prior to starting Biosensors in 1990, Mr. Lu established Asia-based operations for the Medical Division of Gould Inc in Tokyo in 1978. In 1986, he participated in a management-led leveraged buyout of the division from Gould and he continued as president of the Asia-Pacific division through 1988. Mr. Lu took the company to IPO in Nasdaq and it was subsequently sold to British Oxygen Corporation. He served as president of Asia-Pacific with British Oxygen until 1990.
Mr. Lu is active in both international and local medical arena as an entrepreneurial angel investor. Mr. Lu is a General Partner at Majuven Pte Ltd; Foundry Singapore and a venture partner for medical sector at Vertex Venture Management Pte Ltd. With SPRING, Mr. Lu collaborates with Accuron Technologies Ltd (a wholly- owned subsidiary of Temasek) through the Sector Specific Accelerator program.
Yoh-Chie serves on the board of directors for Earlens, Moximed, Ivantis, Visterra (acquired by Otsuka for $430M), and Innoventures.
Carolyn Ng is a Principal of Vertex Ventures HC. At Vertex, Carolyn is responsible for driving venture investments across biotechnology, medical devices and health technology fields. Carolyn currently serves on the Board of Directors for Obsidian Therapeutics, Twentyeight-Seven Therapeutics, Bicycle Therapeutics and Nuvaira. She is also a Board Observer for Visterra (acquired by Otsuka Pharmaceutical for USD430M) and Earlens. She has previously closely supported Vertex’s investment into Twelve (acquired by Medtronic for USD458M). Working across the US, Europe and Asia, she plays an active role in expanding the geographical reach of Vertex HC and its portfolio companies for cross-border collaborations, business development and syndication.
She started her healthcare training in the oncology pharmacy department of the National University Cancer Institute of Singapore, where first hand clinical experience inspired her to pursue scientific research in oncology. As an oncology scientist, she is deeply passionate about innovation that impacts patients’ lives. Prior to joining Vertex, Carolyn was also a Pharma Strategy Consultant at Deallus Consulting, a specialized London-headquartered life sciences consulting firm where she led global strategic projects for clientele comprised of the top 20 global pharmaceutical companies.
Carolyn holds a PhD in Cancer Molecular Biology from the NUS Graduate School for Integrative Sciences and Technology (NGS), where she was a recipient of the prestigious NGS PhD Scholarship. As an inventor and patent holder of a novel small molecule nuclear receptor activator indicated for the treatment of neuroblastoma, her research work was awarded the AAPS-NUS Prize (American Association of Pharmaceutical Society-National University of Singapore). She also holds a BS degree in Pharmacy with First Class Honours from the National University of Singapore, where she received the PSS Prize for Pharmaceutics awarded to the top graduating student in the class.
Outside of Vertex, Carolyn is a retired competitive squash player, a high intensity interval training enthusiast, and an aspiring but untalented oil painter.
Lori Hu is a Principal at Vertex Ventures HC. Ms. Hu joined in 2015 to help establish the US office and manages global healthcare investments in biotech, medical devices and digital health. Before Vertex, Lori was an Associate Director for Business Development at Bristol-Myers Squibb, identifying and executing licensing and partnership transactions. She has also worked with SR One, the corporate venture capital arm of GlaxoSmithKline. Previously, she was a strategy consultant at Accenture, advising biopharmaceutical clients on strategic projects across the US and Asia.
Lori serves on the Board of Directors for Palleon Pharma, and is a board observer for Ivantis, Moximed and Kona. She was involved with the firm’s investment in Twelve, acquired by Medtronic for $458M.
Lori graduated with an MBA from The Wharton School, and MA in International Studies from the University of Pennsylvania where she was a Leonard Lauder Fellow. She also holds a BSE in Biomedical Engineering from Duke University. She is based in the Bay Area.